Evolus Stock Price, News & Analysis

Evolus reported Q4 2022 net revenue of $43.6 million, a 26% increase from Q4 2021, and a full-year revenue of $148.6 million, up 49% year-over-year. The company reaffirmed its 2023 revenue guidance of $180-$190 million, anticipating growth exceeding the overall U.S. aesthetic neurotoxin market. Jeuveau® remains the fastest-growing neurotoxin in the U.S. with over 700 new customer accounts added in Q4 2022, bringing total accounts to above 9,500. The company aims for a positive non-GAAP operating income in Q4 2023 without requiring additional capital.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 14, 2023, from 2:35 to 3:00 PM ET in Miami Beach, Florida. The event will be accessible via an audio webcast on Evolus' investor relations page at www.evolus.com, with a replay available for 90 days post-event. Evolus aims to revolutionize the aesthetic neurotoxin market with its flagship product, Jeuveau^®, a neurotoxin solely dedicated to aesthetics, produced using Hi-Pure™ technology. More details can be found on their official website.

Evolus, Inc. (NASDAQ: EOLS) has launched Nuceiva® in Germany and Austria, marking a significant expansion in the European aesthetic toxin market. This product, approved by the European Commission, targets moderate to severe vertical lines between the eyebrows in adults under 65. The company is partnering with Novvia for distribution in these regions and anticipates entering more European countries and Australia in 2023. The launch follows extensive clinical trials demonstrating the effectiveness of Nuceiva® compared to Botox®. Evolus aims to enhance its market presence and meet growing consumer demand for aesthetic treatments.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, after U.S. markets close. Following this announcement, management will host a conference call and live webcast at 4:30 p.m. ET to discuss the results, including a Q&A session. Participants can join the call via phone or the company's Investor Relations website. A replay of the call will be available afterward. Evolus focuses on the aesthetic neurotoxin market and aims to evolve beauty consumer experiences with innovative products like Jeuveau®, its flagship offering.

Evolus, Inc. (NASDAQ: EOLS) announced that a recent ruling from the Seoul Central District Court in favor of Medytox, Inc. regarding a trade secret dispute will not impact the manufacturing, export, or sale of its products, Jeuveau® and Nuceiva®. Evolus has a global settlement with Medytox, which confirms its right to continue commercializing these products regardless of any ongoing litigation between Medytox and Daewoong Pharmaceutical. This settlement, established in February 2021, ensures that Evolus can maintain its supply chain for these key products.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty firm, announces participation in the SVB Securities Global Biopharma Conference.

Date: February 14, 2023

Time: 11:20-11:50 am ET

Management will discuss their innovative, customer-centric business model and flagship product, Jeuveau^®, which is the first neurotoxin dedicated to aesthetics. An audio webcast will be available on Evolus' investor relations website, with a replay accessible for 90 days post-event.

Evolus (NASDAQ: EOLS) released interim data from its Phase II clinical study of a new "extra-strength" formulation of Jeuveau® at the IMCAS World Congress in Paris. The 40U formulation achieved a notable 6-month effect on Glabellar Lines with a favorable safety profile; no serious adverse events were reported, and 88% of adverse events were mild. The trial, involving 150 patients, aims to evaluate the formulation's efficacy and safety, with final results expected in the second half of 2023. This advancement represents a potential expansion of Evolus' offerings in the aesthetic neurotoxin market.

Evolus, Inc. (NASDAQ: EOLS) announced regulatory approval for Nuceiva® (prabotulinumtoxinA) in Australia, aimed at treating moderate to severe glabellar lines. This approval represents a significant opportunity in one of the largest aesthetic neurotoxin markets outside the U.S. CEO David Moatazedi highlighted the importance of international expansion, aiming for $500 million in total revenue by 2028. Nuceiva is already available in Great Britain and Canada. Evolus plans to launch Nuceiva in Australia in the second half of 2023 following launches in Germany and Austria.

Evolus, Inc. (NASDAQ: EOLS) is set to present interim findings from a Phase 2 study on its neurotoxin product, Jeuveau (prabotulinumtoxinA-xvfs), at the 2023 International Master Course on Aging Science on January 28, 2023 in Paris. The presentation, led by Dr. Rui Avelar, will compare a new 'extra-strength' dose of Jeuveau to existing formulations and Botox for treating moderate to severe glabellar lines. The trial is expected to conclude in H1 2023, with final results to follow later this year. An investor webcast on January 30, 2023 will discuss these findings further.